Results 211 to 220 of about 2,769,024 (292)

Vaccine Safety

, 2018
Destefano, Frank, Offit, Paul A., Fisher, Allison   +2 more
openaire   +1 more source

What Makes an “Ideal” Cell Line for Recombinant Adeno‐Associated Virus Production?

Biotechnology and Bioengineering, EarlyView.
Several host cell types have been used to produce rAAVs to date. Cell line‐specific traits that are beneficial in the context of rAAV manufacturing are reviewed here, with the goal of developing a consensus on the ‘ideal’ characteristics that an rAAV production host should possess (created with Biorender.com).
James Conheady, Nicholas Donohue, Alexandra Bogdanovic, Sharon Davin, Brian Glennon, Niall Barron, C. Mark Smales   +6 more
wiley   +1 more source

MMRV vaccine safety: A comprehensive analysis of adverse events recorded among pediatric populations. [PDF]

Hum Vaccin Immunother
Yan K, Yang G, Yan L, Wu R, Wu L, Wang Y, He P, Yu Q.   +7 more
europepmc   +1 more source

Machine Learning‐Based PAT Tool for Real‐Time Residual Moisture Monitoring in Lyophilized Biopharmaceuticals Using NIR Spectroscopy

Biotechnology and Bioengineering, EarlyView.
ABSTRACT There is a growing demand in the pharmaceutical industry to optimize analytical methodologies, reducing time and resource consumption while ensuring rapid process development and cost‐efficient manufacturing. Indeed, Food and Drug Administration (FDA) introduced the Process Analytical Technology (PAT) as an initiative enabling manufacturers to
Samuele Fiorenza, Mariapia D'Urso, Ambra Massei, Nunzia Falco, Davide Fissore, Enza Torino   +5 more
wiley   +1 more source

Mapping Pediatric Seasonal Influenza Vaccine Safety and Immunogenicity Evidence: A Systematic Review of Clinical Trials. [PDF]

Vaccines (Basel)
Munoz A, Olivares B, Yepes-Perez Y, Chen Y, Ortiz J, Amin M, Zeng M.   +6 more
europepmc   +1 more source

Enhancing the Secretion Systems: Genetic Engineering of Super Bioagents for Effective Plant Disease Control

Biotechnology and Bioengineering, EarlyView.
Genetic engineering (GE) overcomes BCA limits, enabling robust, scalable crop protection. “Super Bioagents” (SBs) use optimized SSs to enhance bioactive molecule delivery. Optimizing SSs enhance precise, sustainable effector deployment for stable disease suppression. SBs use microbiome‐informed design for scalable, next‐gen sustainable crop protection.
Michael Dare Asemoloye
wiley   +1 more source

Safety of COVID-19 and influenza vaccines in children and adolescents with immunocompromised or autoimmune conditions: Findings from the Canadian National Vaccine Safety (CANVAS) network. [PDF]

Hum Vaccin Immunother
Turner C, Vanderkooi OG, Kellner JD, Shulha HP, Muller MP, Sadarangani M, Isenor JE, Marty K, Soe P, Kiely M, Valiquette L, McGeer A, Bettinger JA.   +12 more
europepmc   +1 more source

Purification of Advanced Therapeutics by Flow‐Through Pseudo‐Affinity Chromatography: Bi‐Specific mABs, Fc Fusion Proteins, and Adeno‐Associated Viruses

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Modern biopharmaceutical manufacturing requires purification platforms capable of processing structurally and functionally diverse products while addressing the challenge of removing persistent and high‐risk host cell proteins (HCPs).
Wenning Chu, Eduardo Barbieri, Arianna Minzoni, Shriarjun Shastry, Jacob P. LeBarre, Qingbo Shu, Taufika Williams, Xuanwen Li, Divya Chandra, Xuankuo Xu, Jerome Bill, David Roush, Joseph Taris, Patrick Gilbert, Andre Kiesewetter, Oliver Rammo, Michael Schulte, Christopher Major, Trina Mouchahoir, Steven Cramer, Cristiana Boi, Ruben G. Carbonell, Abraham Lenhoff, Stefano Menegatti   +23 more
wiley   +1 more source

Vaccine safety for individuals receiving immune checkpoint inhibitor therapy: A narrative review of current literature and recommendations for future research. [PDF]

Hum Vaccin Immunother
Sundaram ME.
europepmc   +1 more source

Inventory Replenishment and Transshipment for Distributed Autologous Cell Therapy Manufacturing Networks

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Autologous cell therapy (AuCT) manufacturing networks must balance two competing objectives: reducing cost and improving patient access to time‐sensitive therapy. This study compares three AuCT manufacturing network designs: a centralized network with a single manufacturing facility, a coordinated point‐of‐care (POC) network in which POCs can ...
Zhaowei Li, Chelsea C. White III, Kan Wang, Ben Wang   +3 more
wiley   +1 more source